Neuren Pharmaceuticals : Becoming a substantial holder

Recipient Information To: ASX Company Announcement Off ice Company: ASX Fax #: [phone] From: Lisa De Vargas Company: Lanstead Capital LP Sender Information Email address: [e-mail] (from 75.148.103.89) Phone #: [phone] Sent on: Thursday, July 20 2017 at 4:18 PM EDT

Please find attached a Form 603 from Lanstead Capital LP on behalf of itself and its affilliates in respect of Neuren Pharmaceuticals Limited.

This fax was sent using the FaxZero.com fax service. FaxZero.com has a zero tolerance policy for abuse and junk faxes. If this fax is spam or abusive, please e-mail [e-mail] or send a fax to 855-330-1238, or phone [phone]. Specify fax #[phone]. We will add your fax number to the block list.

1/1

Form 603

Corporations Act 2001

Section 671 B

Notice of initial substantial holder

IQ Company Name/Scheme NEUREN PHARMACEUTICALS LIMITED

ACN/ARSN 1 11 496 130

1. Details of substantial holder (1)

   Name LANSTEAD CAPITAL LP

   ACN/ARSN (if applicable) LP011908

   The holder became a substantial holder on 18 July 2017

2. Details of voting power

   The total number of votes attached to all the voting shares in the company or voting interests in the scheme that the substantial holder or an associate (2) had a relevant interest (3) in on the date the substantial holder became a substantial holder are as follows:

   Class of securities (4)	Number of securities	Person's votes (5)	Voting power (6)
   Ordinary	169,354,839	169,354,839	8.37%

3. Details of relevant interests

   The nature of the relevant interest the substantial holder or an associate had in the following voting securities on the date the substantial holder became a substantial holder are as follows:

   Holder of relevant interest	Nature of relevant interest (7)	Class and number of securities
   Lanstead Capital LP	Direct	169,354,839
   Lanstead Partners Limited	Indirect	169,354,839
   k:;ogent Capital Corp.	Indirect	169,354,839
   Greg Kofford	Indirect	169,354,839
   Mark Holden	Indirect	169,354,839

4. Details of present registered holders

   The persons registered as holders of the securities referred to in paragraph 3 above are as follows:

   Holder of relevant interest	Registered holder of securities	Person entitled to be registered as holder (8)	Class and number of securities
   Lanstead Capital LP	Lanstead Capital LP	Lanstead Capital LP	169,354,839

5. Consideration

The consideration paid for each relevant interest referred to in paragraph 3 above, and acquired in the four months prior to the day that the substantial holder became a substantial holder is as follows:

Holder of relevant interest	Date of acquisition	Consideration (9)		Class and number of securities
Cash	Non-cash	Ordinarv
Lanstead Capital LP	18 July 2017	$10,500,000	169,354,839

1373943 vl

1. Associates

   The reasons the persons named in paragraph 3 above are associates of the substantial holder are as follows:

   Name and ACN/ARSN (if applicable)	Nature of association
   Lanstead Partners Ltd (Company Number 06025782)	General Partner of Lanstead L.P.
   Cogent Capital Corp.	Limited partner of Lanstead Capital L.P.
   K,reg Kofford	Holder of entire issued share capital of Cogent Capital Corp.
   Mark Holden	Limited partner of Lanstead Capital L.P.

2. Addresses

The addresses of persons named in this form are as follows:

Name	Address
Lanstead Capital L.P.	c/o Cooley Services Limited, Dashwood, 69 Old Broad Street, London EC2M QS
Lanstead Partners Ltd	c/o Cooley Services Limited, Dashwood, 69 Old Broad Street, London EC2M QS
::::agent Capital Corp.	c/o Cooley Services Limited, Dashwood, 69 Old Broad Street, London EC2M QS
k,reg Kofford	c/o Cooley Services Limited, Dashwood, 69 Old Broad Street, London EC2M QS
Mark Holden	c/o Cooley Services Limited, Dashwood, 69 Old Broad Street, London EC2MlQS

Signature

print name LISA DE VARGAS capacity COMPANY CONTROLLER

sign here _.}I!

,('. --·'{,,,"'

dme 21/07/2017

--'

DIRECTIONS

1. If there are a number of substantial holders with similar or related relevant interests (eg. a corporation and its related corporations, or the manager and trustee of an equity trust), the names could be included in an annexure to the form. If the relevant interests of a group of persons are essentially similar, they may be referred to throughout the form as a specifically named group if the membership of each group, with the names and addresses of members is clearly set out in paragraph 7 of the form

2. See the definition of "associate" in section 9 of the Corporations Act 2001

3. See the definition of "relevant interest" in sections 608 and 6718(7) of the Corporations Act 2001

4. The voting shares of a company constitute one class unless divided into separate classes

5. The total number of votes attached to all the voting shares in the company or voting interests in the scheme (if any) that the person or an associate has a relevant interest i n.

6. The person's votes divided by the total votes in the body corporate or scheme multiplied by 100

7. Include details ol:

8. any relevant agreement or other circumstances by which the relevant interest was acquired If subsection 6718(4) applies, a copy of any document setting out the terms of any relevant agreement, and a statement by the person giving full and accurate details of any contract, scheme or arrangement, must accompany this form, together with a written statement certifying this contract, scheme or arrangement; and

9. any qualification of the power of a person to exercise, control the exercise of, or influence the exercise of, the voting powers or disposal of the securities to which the relevant interest relates (indicating clearly the particular securities to which the qualification applies}

   See the definition of "relevant agreement" in section 9 of the Corporations Act 2001

10. If the substantial holder is unable to determine the identity of the person ( eg. if the relevant interest arises because of an option} write "unknown".

11. Details of the consideration must include any and all benefits, money and other, that any person from whom a relevant interest was acquired has, or may, become entitled to receive in relation to that acquisition. Details must be included even if the benefit is conditional on the happening or not of a contingency. Details must be included of any benefit paid on behalf of the substantial holder or its associate in relation to the acquisitions, even if they are not paid directly to the person from whom he relevant interest was acquired

12. 1373943 vi